Navigation Links
Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market
Date:10/6/2010

d renal disease.

Use caution when prescribing CAMBIA with drugs known to be hepatotoxic (eg, acetaminophen, certain antibiotics, antiepileptics). Warn patients to avoid acetaminophen containing products while taking CAMBIA. The liver metabolizes almost 100% of diclofenac, and there is insufficient information to support dosing recommendations in patients with hepatic insufficiency. Hepatic effects range from transaminase elevations to liver failure. Discontinue CAMBIA immediately if abnormal liver tests persist or worsen.

NSAIDs can lead to new onset or worsening of preexisting hypertension. Monitor blood pressure closely during therapy. Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs. Note that fluid retention and edema have been observed in some patients taking NSAIDs. Use CAMBIA with caution in patients with fluid retention or heart failure.

Using CAMBIA with other NSAIDs (eg, aspirin) or with anticoagulants (eg, warfarin) is not advised due to increased risk of serious adverse events, such as GI bleeding. Use with caution in patients with a history of ulcers or GI bleeding. Anemia may occur in patients on NSAIDs. In patients on long-term therapy, check hemoglobin or hematocrit upon any sign or symptom of anemia or blood loss.

NSAIDs, including CAMBIA, can cause serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. Discontinue use immediately if rash or other signs of local skin reaction occur.

CAMBIA can harm fetuses. Starting at 30 weeks' gestation, pregnant women should avoid CAMBIA and other NSAIDs as premature closure of the ductus arteriosus in the fetus may occur. Use with caution in nursing mothers as it is not known if diclofenac is excreted in human milk.

The most common adverse events in clinical trials with CAMBIA were nausea and dizziness.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US WorldMeds Acquires Solstice Neurosciences
2. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
3. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
4. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
5. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
6. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
7. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. DMC Sinai-Grace Selects Loopback Communications Readmission Reduction™ Services
11. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...   DigiPath Labs , the cannabis testing subsidiary ... True North Laboratory of Ann Arbor, Michigan ... global supplier of diagnostic solutions for food-borne pathogens, to ... rapid diagnostic test kits to screen for food-borne pathogens ... joint effort is expected to result in the first ...
(Date:7/27/2015)... , July 28, 2015 CTI BioPharma Corp. ... to report its second quarter 2015 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/27/2015)... , July 28, 2015   Regeneron Pharmaceuticals, ... a new global collaboration to discover, develop and commercialize ... immuno-oncology. As part of the agreement, the two companies ... (PD-1) inhibitor currently in Phase 1 testing and plan ... candidates based on ongoing, innovative preclinical programs. ...
Breaking Medicine Technology:DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 2DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 3CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
... WILMINGTON, N.C., Oct. 23 PPD, Inc. ... Sydney, Australia;,Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru; ... key therapeutic areas. The four new offices ... in response to increasing client demand. With,an office ...
... Blueprint for Future, WASHINGTON, Oct. 23 ... latest report from the,Association of Academic Health Centers ... trials in the U.S. and a blueprint for ... academic health,centers nationwide. The infrastructure for clinical trials ...
Cached Medicine Technology:PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal 2AAHC Examines Nation's Clinical Trials Infrastructure 2
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... more common in shipbreaking workers than they are in the general population. Surviving ... to read it now. , Researchers at Taiwan’s National Health Research Institutes ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... a proprietary, web based clinical knowledge system, called “Referral Guidance.” , ... It provides physicians who are anticipating making a subspecialty referral an efficient means ...
(Date:7/28/2015)... ... , ... Women fear developing Alzheimer's disease more than having a heart attack ... are treatable, but there is little an individual can do to arrest the progress ... clinical trial, reports the July 2015 Harvard Women's Health Watch . , "There ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa ... Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty ... esteemed colleagues and peers in the metro area as one of the most respected ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
... Cancer is a common condition in India where beetle and ... found that certain bacteria’s excessive presence may give an early ... report published in the Open Access journal, Journal of Translational ... called squamous cell carcinoma) have six common species of ...
... affects young women and the condition// can sometimes be fatal. ... in the basal ganglia region of the brain. ,People ... and are unaware of the seriousness of their condition.When you ... the famous talented singer Karen Carpenter who died in the ...
... Oxidized phospholipids can be tested in blood to indicate the ... ,A report in the 7th July issue of New England ... phospholipids may indicate the amount of fatty build- up ... future be able to avoid the use of invasive ...
... British Columbia had showed that noise// might be not a ... so when that is effectively used to help the older ... the one sensation that comes in our way of concentration ... related to the disturbances that cause distractions in hearing something. ...
... role of fats, had been debated for a long// time. ... the between the various kinds of fats that are heart ... by banishing one kind of fat totally and taking only ... can help achieve the best possible diet for reducing cholesterol ...
... In a major breakthrough in the advancement of ... scan rare genetic mutation at a fraction of ... array diagonal gel electrophoresis. ,The technology devised ... in collaboration with Bristol, University college London, British ...
Cached Medicine News:Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 2Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 3
Sleek, all-metal head with large-diameter viewing window. 3X magnification....
Provides 30% more magnification and twice the field of view. Adjustable focus....
... FSE are a new series of cryostats ... outside of the cryochamber, which allows easy ... temperature adjustment. Simple, multi-lingual touch-screen display for ... the main touch-screen display. Angle of clamp ...
... Spectra photocoagulator delivers power and reliability ... (DPSS) technology. Diode side-pumping technology drives ... compact Novus Spectra system, and active ... output and system reliability from your ...
Medicine Products: